Navigation Links
Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales

BASKING RIDGE, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today announced that Benjamin Custodio has joined the Company as Executive Vice President of International Sales and a member of the Board of Directors. Mr. Custodio has over 30 years of experience in the pharmaceutical and nutritional supplement industries, specializing in launching new products into international markets.

As Executive Vice President of International Sales, Custodio will leverage his skill set and utilize his strong global relationships to expand the Company's product line globally. Currently, he is the President and CEO of the LCI Group Ltd, a business development group which works with companies around the world in commercializing nutritional supplements, OTC and prescription products. Recently, the LCI Group was successful in coordinating the $360 million sale of the largest custom manufacturer of nutritional supplements in North America. Prior to heading the LCI group, Mr. Custodio was a consultant and member of the Board of Directors of Nu-Life Nutrition Ltd., one of Canada's oldest supplement and nutraceutical companies and once a wholly-owned subsidiary of Vitaquest International Inc., the world's leading custom manufacturer of nutritional and lifestyle products. Over his 30 plus years of industry experience, Mr. Custodio, has acted as the Head of Beverage Unit for Del Monte, President of Wampole Brands, the oldest nutraceutical company in Canada, was an executive with Ciba Geigy/Novartis, and handled international assignments with Johnson & Johnson International.

"Benjamin brings a wealth of experience and contacts to Millennium Biotechnologies," stated Mark Mirken, Chief Executive Officer of Millennium Biotechnologies. "His strong and well respected relationships in Asia will be the source of our international growth. With Benjamin at the helm of international expansion, we expect to achieve an immediate increase in our overseas sales at enhanced profit margins."

According to newly elected board member, Benjamin Custodio, "Millennium Biotechnologies is emerging as a leader in the development of targeted nutritional products in the Clinical, Long Term Care, and Sports markets. With the recent launch of the Company's ready-to-drink products, Resurgex Essential and Resurgex Essential Plus, now is the time for aggressive international expansion. I look forward to working with the Company in leveraging my international contacts for the benefit of its shareholders and believe that numerous overseas expansion opportunities exist in the very near term."

About Millennium

Millennium Biotechnologies is a leader in the development, of targeted nutritional products in the Clinical Nutrition Market and Sports Nutrition Market. Millennium's six marketed products form an advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Millennium's technology, opportunities for the Millennium, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of Millennium's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Millennium's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ('SEC'). Millennium Biotechnologies, Inc.

SOURCE Millennium Biotechnologies Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jerome Wilson Joins PRA Internationals Late Phase Service Group
2. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
3. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
4. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
5. Food and Beverage Giant Joins Kannapolis Research Center
6. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
7. Chief Technology Officer Joins ACAMP
8. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
9. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
10. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
11. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is ... 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... wide range of applications such as, but not limited to, biotechnology, biomedical, drug ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):